1 / 2

Human Insulin Market - Emerging Markets and Expected Patent Expiry of Key HI Drugs

The report " Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020”, The Global Human Insulin Market Is Poised to reach ~USD 39.13 Billion by 2020, growing at a CAGR of 8.1% from 2015 to 2020 and studies the global human insulin market over the forecast period of 2015 to 2020.

Sandeepguha21
Download Presentation

Human Insulin Market - Emerging Markets and Expected Patent Expiry of Key HI Drugs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Human Insulin Market - Emerging Markets and Expected Patent Expiry of Key HI Drugs The report " Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020”, The Global Human Insulin Market Is Poised to reach ~USD 39.13 Billion by 2020, growing at a CAGR of 8.1% from 2015 to 2020 and studies the global human insulin market over the forecast period of 2015 to 2020. Browse 75 market tables and 53 figures spread through 157 pages and in-depth TOC on "Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020" http://www.marketsandmarkets.com/Market-Reports/human-insulin-market-229295783.html Early buyers will receive 10% customization on reports. Industry Insights: Industry growth is driven by growing diabetes patient population, increasing population exposure to key risk factors leading to diabetes, rising market demand for human insulin analogs, technological advancements in the field of human insulin delivery devices, and favorable medical reimbursements are driving the growth of human insulin market during the forecast period. However, stringent regulatory requirements for product approval are restraining the growth of this market. Get The PDF Brochure For This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=229295783 Geographical Scenario: Based on geography, North America is expected to hold the largest share of the human insulin market, followed by Europe. Additionally, Asia-Pacific is expected to grow at the highest CAGR during the forecast period (2015 to 2020). Strong market growth witnessed in the North American human insulin market can be attributed to factors such as significant patent protection for several human insulin biosimilar brands in the U.S., continuous updation of medical reimbursement guidelines in the U.S. for diabetes treatment, and extensive & well-established distribution network of market players for human insulin products. Request Sample: http://www.marketsandmarkets.com/requestsample.asp?id=152603894 Industry Leaders: The prominent players in the Vaccine Adjuvants Market are Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (U.A.E.), Ypsomed AG (Switzerland), Becton, Dickinson and Company (U.S.), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland), and Biodel Inc. (U.S.) About MarketsandMarkets™: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

  2. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441

More Related